CEACAM5 and neoplasm: Malignancy workup, including tumor biomarkers (Carcinoembryonic Antigen (CEA), Cancer Antigen 19‐9 (CA19‐9), and Cancer Antigen 125 (CA125)), spiral chest, abdominal, and pelvic Computed Tomography (CT) scans, mammography, gynecologic examination, and occult blood test, was negative.